In Vivo CAR T: A New Route to Treating Autoimmune Disease - Scorecard - MDSpire

In Vivo CAR T: A New Route to Treating Autoimmune Disease

How targeted in vivo CAR T delivery could pave the way for autoimmune disease treatments

  • By

  • Ying K. Tam

  • Sean Semple

  • July 13, 2026

  • 7 min

Share

Clinical Scorecard: In Vivo CAR T: A New Route to Treating Autoimmune Disease

At a Glance

CategoryDetail
ConditionAutoimmune Diseases
Key MechanismsIn vivo generation of CAR T-cells targeting B-cells to reset the immune system.
Target PopulationPatients with autoimmune conditions such as lupus and multiple sclerosis.
Care SettingClinical research and specialized medical centers.

Key Highlights

  • In vivo CAR T-cell therapy shows promise for treating autoimmune diseases.
  • Technological advancements enable targeted delivery of CAR T-cells.
  • Modified lipid nanoparticles (LNP) improve specificity and reduce liver uptake.
  • DARPins offer a smaller, more effective targeting alternative to antibodies.
  • Potential for long-term remission in autoimmune patients with high unmet needs.

Guideline-Based Recommendations

Diagnosis

  • Identify autoimmune conditions with high B-cell involvement.

Management

  • Consider in vivo CAR T-cell therapy for eligible patients.

Monitoring & Follow-up

  • Assess safety and efficacy of in vivo CAR T-cell therapies in clinical trials.

Risks

  • Evaluate the potential for immune responses and side effects from therapy.

Patient & Prescribing Data

Patients with autoimmune diseases who may benefit from B-cell targeting.

In vivo CAR T-cell therapy may provide a more accessible treatment option.

Clinical Best Practices

  • Utilize modified LNP for targeted delivery of CAR T-cell therapies.
  • Monitor patient responses closely during therapy.
  • Engage in clinical trials to evaluate new CAR T-cell therapies.

Related Resources & Content

    Original Source(s)

    In Vivo CAR T: A New Route to Treating Autoimmune Disease

    • by Ying K. Tam, Sean Semple

    • July 13, 2026

    Related Content

    Meta-analysis of factors for osteonecrosis in systemic lupus erythematosus: integration of comprehensive literatures and multicenter databases

    Side Effects: Bro Science, Actually

    Creatine's ATP-buffering trick isn't just for biceps. In mice, it juices up dendritic cells' energy supply, sharpening T-cell priming and shrinking tumors on daily injections. Human DCs got the memo too, at least in a dish. Early days, but a fun plot twist for gym-bag chemistry.

    First HIV-Positive-to-HIV-Positive Lung Transplant Reported

    The procedure was performed under a HOPE Act research protocol at an NYU Langone Health center the institution said is among the limited number of US transplant centers equipped and approved to perform HOPE lung transplants.